5 completed, 1 terminated. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
Follow laquinimod: new trials by email Literature Review of laquinimod trials Research Report on laquinimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo Placebo, Laquinimod - Primary Progressive Multiple Sclerosis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 374 | 2015-01-12 | 2022-03-10 |
| A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod Laquinimod, Placebo - Huntington's Disease | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 352 | 2014-10-28 | 2020-05-04 |
| A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis Laquinimod, Placebo - Lupus Arthritis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 82 | 2010-10-04 | 2022-07-07 |
| A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone - Lupus Nephritis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 46 | 2010-09-01 | 2022-03-09 |
| Laquinimod Phase IIa Study in Active Crohn's Disease Laquinimod, placebo - Crohn's Disease | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 180 | 2010-05-01 | 2015-03-20 |
| An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease Laquinimod, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Teva Pharmaceutical Industries, Ltd. | 257 | 2005-12-07 | 2019-03-27 |
Lupus Erythematosus, Systemic (2) · Crohn Disease (1) · Huntington Disease (1) · Lupus Nephritis (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Teva Branded Pharmaceutical Products R&D, Inc. (5) · Teva Pharmaceutical Industries, Ltd. (1)
United Kingdom (5) · Canada (4) · Italy (4) · Russia (4) · Spain (4) · United States (4) · Germany (3) · Netherlands (3) · Poland (3) · Czechia (2) · France (2) · Israel (2) · Belgium (1) · Hungary (1) · Portugal (1)
Geert D'Haens, MD PhD (1) · Giancarlo Comi (1)
PMID 25281416, PMID 27296315, PMID 32651286, PMID 36163349, PMID 38280392
2014 (2), 2005 (1)